{"transactions":[{"id":1066589,"issuer":{"id":4991,"kind":"organization","name":"Design Therapeutics, Inc."},"owners":[{"id":76515,"kind":"person","name":"William Arsani","position":1,"cik":"0001848372","reported_name":"William Arsani","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-14T20:15:08.000Z","date":"2025-08-13","kind":"sale","planned":false,"acquired":false,"shares":217627,"price":5.25,"value":1142541.75,"ownership":{"direct":false,"nature":"By Logos Opportunities Fund II LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Logos Global Management LP is the investment advisor of private funds, including Logos Opportunities Fund II LP (\"LOF II\"). Logos Opportunities GP LLC (\"GP I\") is the general partner of LOF II. The Reporting Person is the Managing Member of GP I. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":1000000,"source":{"system":"sec-edgar","filing":"0001415889-25-021842","document":"form4-08142025_040805.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1807120/000141588925021842/form4-08142025_040805.xml","form_type":"4"}},{"id":1066588,"issuer":{"id":4991,"kind":"organization","name":"Design Therapeutics, Inc."},"owners":[{"id":76515,"kind":"person","name":"William Arsani","position":1,"cik":"0001848372","reported_name":"William Arsani","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-14T20:15:08.000Z","date":"2025-08-13","kind":"sale","planned":false,"acquired":false,"shares":345000,"price":5.25,"value":1811250.0,"ownership":{"direct":false,"nature":"By Logos Global Master Fund LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Logos GP LLC (\"Fund GP\") is the general partner of Logos Global Master Fund LP (the \"Fund\"). The Reporting Person is the Managing Member of Fund GP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":2655000,"source":{"system":"sec-edgar","filing":"0001415889-25-021842","document":"form4-08142025_040805.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807120/000141588925021842/form4-08142025_040805.xml","form_type":"4"}},{"id":1113582,"issuer":{"id":4991,"kind":"organization","name":"Design Therapeutics, Inc."},"owners":[{"id":76515,"kind":"person","name":"William Arsani","position":1,"cik":"0001848372","reported_name":"William Arsani","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-12T20:30:20.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in equal monthly installments over 12 months following June 10, 2025 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders."}],"balance_after":19000,"derivative":{"exercise_price":4.01,"expiration_date":"2035-06-09","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001415889-25-016959","document":"form4-06122025_040614.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807120/000141588925016959/form4-06122025_040614.xml","form_type":"4"}},{"id":1436069,"issuer":{"id":4991,"kind":"organization","name":"Design Therapeutics, Inc."},"owners":[{"id":76515,"kind":"person","name":"William Arsani","position":1,"cik":"0001848372","reported_name":"William Arsani","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-12T20:30:21.000Z","date":"2024-08-09","kind":"sale","planned":false,"acquired":false,"shares":814874,"price":4.25,"value":3463214.5,"ownership":{"direct":false,"nature":"By Logos SPV I LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Logos Global Management LP is the investment advisor of private funds, including Logos Opportunities Fund II LP (\"LOF II\") and Logos SPV 1 LP (\"SPV 1\"). Logos Opportunities GP LLC (\"GP I\") is the general partner of LOF II. Logos Opportunities II GP LLC (\"GP II\") is the general partner of SPV 1. The Reporting Person is the Managing Member of both GP I and GP II. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-24-021086","document":"form4-08122024_080818.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807120/000141588924021086/form4-08122024_080818.xml","form_type":"4"}},{"id":1477400,"issuer":{"id":4991,"kind":"organization","name":"Design Therapeutics, Inc."},"owners":[{"id":76515,"kind":"person","name":"William Arsani","position":1,"cik":"0001848372","reported_name":"William Arsani","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-17T21:00:23.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in equal monthly installments over 12 months following June 13, 2024 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders."}],"balance_after":19000,"derivative":{"exercise_price":3.82,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001415889-24-017241","document":"form4-06172024_050620.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807120/000141588924017241/form4-06172024_050620.xml","form_type":"4"}},{"id":1787354,"issuer":{"id":4991,"kind":"organization","name":"Design Therapeutics, Inc."},"owners":[{"id":76515,"kind":"person","name":"William Arsani","position":1,"cik":"0001848372","reported_name":"William Arsani","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-06T21:13:04.000Z","date":"2021-03-30","kind":"purchase","planned":false,"acquired":true,"shares":700000,"price":20,"value":14000000.0,"ownership":{"direct":false,"nature":"By Logos Global Master Fund LP"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This Form 4 is being amended to correct the amount of securities beneficially owned by the Reporting Person.  This error resulted in the misreporting of the amount of securities beneficially owned by the Reporting Person on subsequent reports."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Logos GP LLC (\"Fund GP\") is the general partner of Logos Global Master Fund LP (the \"Fund\"). The Reporting Person is the Managing Member of Fund GP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":700000,"source":{"system":"sec-edgar","filing":"0001209191-23-048441","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1807120/000120919123048441/doc4a.xml","form_type":"4/A","original_submission_date":"2021-04-01"}},{"id":1787353,"issuer":{"id":4991,"kind":"organization","name":"Design Therapeutics, Inc."},"owners":[{"id":76515,"kind":"person","name":"William Arsani","position":1,"cik":"0001848372","reported_name":"William Arsani","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-06T21:13:04.000Z","date":"2021-03-30","kind":"exercise","planned":false,"acquired":true,"shares":814874,"ownership":{"direct":false,"nature":"By Logos SPV 1 LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This Form 4 is being amended to correct the amount of securities beneficially owned by the Reporting Person.  This error resulted in the misreporting of the amount of securities beneficially owned by the Reporting Person on subsequent reports."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Logos Global Management LP is the investment advisor of private funds, including Logos Opportunities Fund II LP (\"LOF II\") and Logos SPV 1 LP (\"SPV 1\"). Logos Opportunities GP LLC (\"GP I\") is the general partner of LOF II. Logos Opportunities II GP LLC (\"GP II\") is the general partner of SPV 1. The Reporting Person is the Managing Member of both GP I and GP II. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":814874,"source":{"system":"sec-edgar","filing":"0001209191-23-048441","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1807120/000120919123048441/doc4a.xml","form_type":"4/A","original_submission_date":"2021-04-01"}},{"id":1787352,"issuer":{"id":4991,"kind":"organization","name":"Design Therapeutics, Inc."},"owners":[{"id":76515,"kind":"person","name":"William Arsani","position":1,"cik":"0001848372","reported_name":"William Arsani","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-06T21:13:04.000Z","date":"2021-03-30","kind":"exercise","planned":false,"acquired":true,"shares":1217627,"ownership":{"direct":false,"nature":"By Logos Opportunities Fund II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This Form 4 is being amended to correct the amount of securities beneficially owned by the Reporting Person.  This error resulted in the misreporting of the amount of securities beneficially owned by the Reporting Person on subsequent reports."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Logos Global Management LP is the investment advisor of private funds, including Logos Opportunities Fund II LP (\"LOF II\") and Logos SPV 1 LP (\"SPV 1\"). Logos Opportunities GP LLC (\"GP I\") is the general partner of LOF II. Logos Opportunities II GP LLC (\"GP II\") is the general partner of SPV 1. The Reporting Person is the Managing Member of both GP I and GP II. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":1217627,"source":{"system":"sec-edgar","filing":"0001209191-23-048441","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807120/000120919123048441/doc4a.xml","form_type":"4/A","original_submission_date":"2021-04-01"}},{"id":1793132,"issuer":{"id":4991,"kind":"organization","name":"Design Therapeutics, Inc."},"owners":[{"id":76515,"kind":"person","name":"William Arsani","position":1,"cik":"0001848372","reported_name":"William Arsani","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-30T22:02:07.000Z","date":"2023-08-29","kind":"purchase","planned":false,"acquired":true,"shares":1960000,"price":2.44,"value":4782400.0,"ownership":{"direct":false,"nature":"By Logos Global Master Fund LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The weighted average purchase price for the transaction was $2.44.  The shares were purchased at a range of prices between $2.29 and $2.50, inclusive.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Logos GP LLC (\"Fund GP\") is the general partner of Logos Global Master Fund LP (the \"Fund\"). The Reporting Person is the Managing Member of Fund GP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":3000000,"source":{"system":"sec-edgar","filing":"0001209191-23-047773","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1807120/000120919123047773/doc4.xml","form_type":"4"}},{"id":1793131,"issuer":{"id":4991,"kind":"organization","name":"Design Therapeutics, Inc."},"owners":[{"id":76515,"kind":"person","name":"William Arsani","position":1,"cik":"0001848372","reported_name":"William Arsani","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-30T22:02:07.000Z","date":"2023-08-28","kind":"purchase","planned":false,"acquired":true,"shares":275000,"price":2.15,"value":591250.0,"ownership":{"direct":false,"nature":"By Logos Global Master Fund LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The weighted average purchase price for the transaction was $2.15.  The shares were purchased at a range of prices between $2.11 and $2.1677, inclusive.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Logos GP LLC (\"Fund GP\") is the general partner of Logos Global Master Fund LP (the \"Fund\"). The Reporting Person is the Managing Member of Fund GP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":1040000,"source":{"system":"sec-edgar","filing":"0001209191-23-047773","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807120/000120919123047773/doc4.xml","form_type":"4"}},{"id":1870160,"issuer":{"id":4991,"kind":"organization","name":"Design Therapeutics, Inc."},"owners":[{"id":76515,"kind":"person","name":"William Arsani","position":1,"cik":"0001848372","reported_name":"William Arsani","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-02T20:31:38.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in equal monthly installments over 12 months following May 31, 2023 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders."}],"balance_after":15000,"derivative":{"exercise_price":5.63,"expiration_date":"2033-05-30","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-23-033782","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807120/000120919123033782/doc4.xml","form_type":"4"}},{"id":2230092,"issuer":{"id":4991,"kind":"organization","name":"Design Therapeutics, Inc."},"owners":[{"id":76515,"kind":"person","name":"William Arsani","position":1,"cik":"0001848372","reported_name":"William Arsani","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-16T21:08:58.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in equal monthly installments over 12 months following June 15, 2022 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders."}],"balance_after":15000,"derivative":{"exercise_price":13.69,"expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-22-037514","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807120/000120919122037514/doc4.xml","form_type":"4"}},{"id":2321677,"issuer":{"id":4991,"kind":"organization","name":"Design Therapeutics, Inc."},"owners":[{"id":76515,"kind":"person","name":"William Arsani","position":1,"cik":"0001848372","reported_name":"William Arsani","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-22T23:28:14.000Z","date":"2022-03-21","kind":"purchase","acquired":true,"shares":25000,"price":18.9872,"value":474680.0,"ownership":{"direct":false,"nature":"By Logos Global Master Fund LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Logos Global Management LP (\"LGM\") is the investment adviser of private funds, including Logos Global Master Fund LP (the \"Fund\"). Logos GP LLC (\"Fund GP\") is the general partner of the Fund. The Reporting Person is the Manager of Fund GP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":2797501,"source":{"system":"sec-edgar","filing":"0001209191-22-020638","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1807120/000120919122020638/doc4.xml","form_type":"4"}},{"id":2581845,"issuer":{"id":4991,"kind":"organization","name":"Design Therapeutics, Inc."},"owners":[{"id":76515,"kind":"person","name":"William Arsani","position":1,"cik":"0001848372","reported_name":"William Arsani","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-02T21:06:13.000Z","date":"2021-08-31","kind":"purchase","acquired":true,"shares":40000,"price":15.45,"value":618000.0,"ownership":{"direct":false,"nature":"By Logos Global Master Fund LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average purchase price for the transaction was $15.45.  The shares were purchased at a range of prices between $15.00 and $15.69, inclusive.  Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Logos Global Management LP (\"LGM\") is the investment adviser of private funds, including Logos Global Master Fund LP (the \"Fund\"). Logos GP LLC (\"Fund GP\") is the general partner of the Fund. The Reporting Person is the Manager of Fund GP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":2772501,"source":{"system":"sec-edgar","filing":"0001209191-21-054492","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1807120/000120919121054492/doc4.xml","form_type":"4"}},{"id":2764484,"issuer":{"id":4991,"kind":"organization","name":"Design Therapeutics, Inc."},"owners":[{"id":76515,"kind":"person","name":"William Arsani","position":1,"cik":"0001848372","reported_name":"William Arsani","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-04-01T22:12:37.000Z","date":"2021-03-30","kind":"exercise","acquired":false,"shares":1328245,"ownership":{"direct":false,"nature":"By Logos SPV 1 LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect.  The Preferred Stock has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect.  The Preferred Stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect.  The Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect.  The Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a managing member of Logos Opportunities Fund II, L.P. and Logos SPV 1 LP.  The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":814874},"source":{"system":"sec-edgar","filing":"0001209191-21-024224","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1807120/000120919121024224/doc4.xml","form_type":"4"}},{"id":2764483,"issuer":{"id":4991,"kind":"organization","name":"Design Therapeutics, Inc."},"owners":[{"id":76515,"kind":"person","name":"William Arsani","position":1,"cik":"0001848372","reported_name":"William Arsani","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-04-01T22:12:37.000Z","date":"2021-03-30","kind":"exercise","acquired":false,"shares":1984733,"ownership":{"direct":false,"nature":"By Logos Opportunities Fund II, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect.  The Preferred Stock has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect.  The Preferred Stock has no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect.  The Preferred Stock has no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect.  The Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a managing member of Logos Opportunities Fund II, L.P. and Logos SPV 1 LP.  The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1217627},"source":{"system":"sec-edgar","filing":"0001209191-21-024224","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1807120/000120919121024224/doc4.xml","form_type":"4"}},{"id":2764482,"issuer":{"id":4991,"kind":"organization","name":"Design Therapeutics, Inc."},"owners":[{"id":76515,"kind":"person","name":"William Arsani","position":1,"cik":"0001848372","reported_name":"William Arsani","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-01T22:12:37.000Z","date":"2021-03-30","kind":"purchase","acquired":true,"shares":700000,"price":20,"value":14000000.0,"ownership":{"direct":false,"nature":"By Logos Global Master Fund LP"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Logos Global Management LP (\"LGM\") is the investment adviser of private funds, including Logos Global Master Fund LP (the \"Fund\"). Logos GP LLC (\"Fund GP\") is the general partner of the Fund. The Reporting Person is the Manager of Fund GP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":2732501,"source":{"system":"sec-edgar","filing":"0001209191-21-024224","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1807120/000120919121024224/doc4.xml","form_type":"4"}},{"id":2764481,"issuer":{"id":4991,"kind":"organization","name":"Design Therapeutics, Inc."},"owners":[{"id":76515,"kind":"person","name":"William Arsani","position":1,"cik":"0001848372","reported_name":"William Arsani","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-01T22:12:37.000Z","date":"2021-03-30","kind":"exercise","acquired":true,"shares":814874,"ownership":{"direct":false,"nature":"By Logos SPV I LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect.  The Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a managing member of Logos Opportunities Fund II, L.P. and Logos SPV 1 LP.  The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":2032501,"source":{"system":"sec-edgar","filing":"0001209191-21-024224","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1807120/000120919121024224/doc4.xml","form_type":"4"}},{"id":2764480,"issuer":{"id":4991,"kind":"organization","name":"Design Therapeutics, Inc."},"owners":[{"id":76515,"kind":"person","name":"William Arsani","position":1,"cik":"0001848372","reported_name":"William Arsani","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-01T22:12:37.000Z","date":"2021-03-30","kind":"exercise","acquired":true,"shares":1217627,"ownership":{"direct":false,"nature":"By Logos Opportunities Fund II, L.P."},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect.  The Preferred Stock has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a managing member of Logos Opportunities Fund II, L.P. and Logos SPV 1 LP.  The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":1217627,"source":{"system":"sec-edgar","filing":"0001209191-21-024224","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807120/000120919121024224/doc4.xml","form_type":"4"}},{"id":2769436,"issuer":{"id":4991,"kind":"organization","name":"Design Therapeutics, Inc."},"owners":[{"id":76515,"kind":"person","name":"William Arsani","position":1,"cik":"0001848372","reported_name":"William Arsani","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-03-29T21:56:24.000Z","date":"2021-03-25","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in equal monthly installments over the 12 months following March 25, 2021."}],"balance_after":15000,"derivative":{"exercise_price":20,"expiration_date":"2031-03-24","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-21-023466","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807120/000120919121023466/doc4.xml","form_type":"4"}}]}